| Titolo |
Pubblicato in |
Anno |
| Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
BIOMEDICINES |
2024 |
| Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2024 |
| Blood Extracellular Vesicles beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients |
BIOMEDICINES |
2024 |
| Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer |
ONCOLOGY RESEARCH |
2024 |
| Pregnancy-associated breast cancer: a diagnostic and therapeutic challenge |
DIAGNOSTICS |
2023 |
| Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer |
FRONTIERS IN ONCOLOGY |
2023 |
| Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer |
CELLS |
2023 |
| Is cancer an intelligent species? |
CANCER METASTASIS REVIEWS |
2023 |
| An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile |
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
2022 |
| RAS mutation conversion in bevacizumab-treated metastatic colorectal cancer patients: a liquid biopsy based study |
CANCERS |
2022 |
| Precision medicine in breast cancer: do MRI biomarkers identify patients who truly benefit from the Oncotype DX Recurrence Score® Test? |
DIAGNOSTICS |
2022 |
| Eribulin in brain metastases of breast cancer. outcomes of the EBRAIM prospective observational trial |
FUTURE ONCOLOGY |
2021 |
| Role of chemotherapy in vulvar cancers: time to rethink standard of care? |
CANCERS |
2021 |
| Sequential isolation and characterization of single CTCs and large CTC clusters in metastatic colorectal cancer patients |
CANCERS |
2021 |
| Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence |
JOURNAL OF CELLULAR PHYSIOLOGY |
2020 |
| Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer |
FRONTIERS IN ONCOLOGY |
2020 |
| T-DM1 Efficacy in patients with HER2-positive metastatic breast cancer progressing after a Taxane Plus Pertuzumab and Trastuzumab. An italian multicenter observational study |
CLINICAL BREAST CANCER |
2020 |
| Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer |
ONCOTARGET |
2020 |
| Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in ER+/HERr2− patients: A propensity score-matched analysis of a multicenter retrospective patient series |
JOURNAL OF PERSONALIZED MEDICINE |
2020 |
| Oncotype DX predictive nomogram for recurrence score output: the novel system ADAPTED01 based on quantitative immunochemistry analysis |
CLINICAL BREAST CANCER |
2020 |
